More comprehensive, more informative, more streamlined myeloid MRD detection

The Ion Torrent Oncomine Myeloid MRD Assays (RUO) on the Ion GeneStudio S5 System is a complete NGS testing solution for myeloid measurable residual disease (MRD) research. Highly sensitive AmpliSeq HD technology enables a limit of detection as low as 0.05% allele frequency.

Unlike traditional methods, NGS allows you to obtain informative data across a broad range of biomarkers simultaneously. A DNA and an RNA assay enable comprehensive assessment of genetic alterations, including SNVs, indels, and gene fusions. This streamlined approach to MRD analysis also features a complete informatics and reporting solution that simplifies data analysis and interpretation

On Demand Webinar: Genomic profiling from initial assessment to detection of measurable residual disease (MRD): how NGS can rapidly deliver key insights for myeloid neoplasms.

Dr. Bevan Tandon will review ongoing research in his laboratory using the Oncomine Myeloid Assay GX, an NGS-based test capable of delivering results in just 1-2 days. He will also share his experience with the upcoming Oncomine Myeloid MRD Assay (RUO), a highly sensitive NGS test for measurable residual disease (MRD) assessment that can identify mutations occurring at very low frequencies. Dr. Tandon will share recent analytical data from his team and offer his perspective on the value of NGS in hematopathology studies.

Bevan Tandon, MD

Director, Hematopathology and Molecular Pathology


MRD Assay content summary

The assays feature DNA and RNA targets for myeloid MRD analysis, allowing simultaneous profiling of single nucleotide variants (SNVs), insertions and deletions (indels), tandem duplications, and key gene fusions.

 

These carefully curated targets are relevant for all categories of myeloid neoplasms, including Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), and Myeloproliferative Neoplasms (MPN) samples.

 

DNA panel

  • 33 genes, including 2 full genes and FLT3-ITDs
  • Optional 22-amplicon micro-haplotype panel for
    chimerism analysis
DNA Assay - Gene Targets
ABL1 FLT3** NRAS TP53*
ASXL1 GATA2 PHF6 U2AF1
BCOR IDH1 PTPN11 WT1
BRAF IDH2 RUNX1  
CALR JAK2 SETBP1  
CBL KIT SF3B1  
CEBPA* KRAS SH2B3  
CSF3R MPL SRSF2  
DNMT3A MYD88 STAG2  
EZH2 NPM1 TET2  

RNA panel

  • 42 fusion driver genes
  • 990 unique fusions
  • 6 genes with exon splicing variants
  • 5 expression control genes
RNA Assay - Fusion Driver Genes Expression Controls Exon Splicing Variants
ABL1 FUS MYBL1 RARA ABL1 KMT2A
ABL2 GLIS2 MYH11 RARB GUSB RUNX1
ALK HMGA2 NOTCH1 RARG PSMB2 NOTCH1
BCL2 JAK2 NTRK1 RET PUM1 ETV6
BRAF KAT6A (MOZ) NTRK2 RUNX1 TRIM27 IKZF1
CCND1 KAT6B NTRK3 TAL1   NTRK1
CREBBP KMT2A (includes PTD)* NUP214 TCF3    
CSF1R MECOM NUP98 TCF4    
EGFR MLLT10 PAX5 TFE3    
ETV6 MRTFA (MLK1) PDGFRA ZNF384    
FGFR1   PDGFRB      

Chimerism analysis

An optional 22-amplicon DNA panel is included for chimerism analysis in post–allogeneic stem cell transplantation (allo-HSCT) research samples.

 

This innovative NGS technique measures the ratio of donor/recipient DNA down to 0.2% allele frequency. Unlike traditional methods that rely on qualitative analysis, NGS provides digital quantification of allele mixtures to identify low-frequency, disease-associated markers with high sensitivity.


Streamlined workflow

The Oncomine Myeloid MRD Assays (RUO) include a fully integrated workflow based on the Ion GeneStudio S5 System. The entire process can be completed in 2–3 days with roughly 2 hours of hands-on time.


Integrated informatics and reporting

The solution includes an integrated analysis pipeline that allows labs to easily analyze samples without needing deep informatics expertise typically required for other assays.

 

Easily visualize allele frequencies for target genes over a time series using Ion Reporter analysis tools.


Ordering information


Ready to speak to a Thermo Fisher representative?

We will be happy to answer your questions and provide a demo of our NGS solutions.

For Research Use Only. Not for use in diagnostic procedures.